| Year |
Citation |
Score |
| 2023 |
Beers JL, Authement AK, Isoherranen N, Jackson KD. Cytosolic Enzymes Generate Cannabinoid Metabolites 7-Carboxycannabidiol and 11-Nor-9-carboxytetrahydrocannabinol. Acs Medicinal Chemistry Letters. 14: 614-620. PMID 37197460 DOI: 10.1021/acsmedchemlett.3c00017 |
0.31 |
|
| 2022 |
Yadav AS, Stevison F, Kosaka M, Wong S, Kenny JR, Amory JK, Isoherranen N. Isotretinoin and its metabolites alter mRNA of multiple enzyme and transporter genes in vitro but downregulation of OATP1B1 does not translate to the clinic. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 35545255 DOI: 10.1124/dmd.122.000882 |
0.343 |
|
| 2021 |
Fay EE, Czuba LC, Sager JE, Shum S, Stephenson-Famy A, Isoherranen N. Pregnancy has no Clinically Significant Effect on the Pharmacokinetics of Bupropion or Its Metabolites. Therapeutic Drug Monitoring. PMID 33814540 DOI: 10.1097/FTD.0000000000000885 |
0.304 |
|
| 2021 |
Shum S, Isoherranen N. Human Fetal Liver Metabolism of Oxycodone Is Mediated by CYP3A7. The Aaps Journal. 23: 24. PMID 33438174 DOI: 10.1208/s12248-020-00537-x |
0.304 |
|
| 2020 |
Kaartinen TJK, Tornio A, Tapaninen T, Launiainen T, Isoherranen N, Niemi M, Backman JT. Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19 and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19. Clinical Pharmacology and Therapeutics. PMID 32558923 DOI: 10.1002/Cpt.1949 |
0.367 |
|
| 2020 |
Shum S, Jing J, Petroff R, Crouthamel B, Grant KS, Burbacher TM, Isoherranen N. Maternal-fetal disposition of domoic acid following repeated oral dosing during pregnancy in nonhuman primate. Toxicology and Applied Pharmacology. 115027. PMID 32360744 DOI: 10.1016/J.Taap.2020.115027 |
0.319 |
|
| 2020 |
Czuba LC, Zhong G, Yabut KC, Isoherranen N. Analysis of vitamin A and retinoids in biological matrices. Methods in Enzymology. 637: 309-340. PMID 32359651 DOI: 10.1016/Bs.Mie.2020.02.010 |
0.35 |
|
| 2020 |
Huang W, Czuba LC, Isoherranen N. Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine. The Journal of Pharmacology and Experimental Therapeutics. PMID 32198137 DOI: 10.1124/Jpet.120.264994 |
0.314 |
|
| 2020 |
Zhong G, Seaman C, Xi H, Paragas E, Jones J, Isoherranen N. A9 - Aldehyde oxidase contributes to all-trans-retinoic acid biosynthesis in human liver Drug Metabolism and Pharmacokinetics. 35. DOI: 10.1016/J.Dmpk.2020.04.263 |
0.333 |
|
| 2020 |
Yabut K, Isoherranen N. P176 - Binding proteins have enzyme specific effects on xenobiotic metabolism Drug Metabolism and Pharmacokinetics. 35. DOI: 10.1016/J.Dmpk.2020.04.177 |
0.346 |
|
| 2020 |
Shum S, Isoherranen N. P132 - Contribution of fetal liver and placenta to maternal-fetal oxycodone disposition Drug Metabolism and Pharmacokinetics. 35. DOI: 10.1016/J.Dmpk.2020.04.133 |
0.334 |
|
| 2020 |
Czuba L, Fay E, Sagar J, Stephenson-Famy A, Shum S, Isoherranen N. P42 - Maternal-fetal pharmacokinetics of bupropion and its metabolites Drug Metabolism and Pharmacokinetics. 35. DOI: 10.1016/J.Dmpk.2020.04.043 |
0.346 |
|
| 2019 |
Huang W, Isoherranen N. Sampling site has a critical impact on PBPK modeling. The Journal of Pharmacology and Experimental Therapeutics. PMID 31604807 DOI: 10.1124/Jpet.119.262154 |
0.306 |
|
| 2019 |
Isoherranen N, Zhong G. Biochemical and physiological importance of the CYP26 retinoic acid hydroxylases. Pharmacology & Therapeutics. 107400. PMID 31419517 DOI: 10.1016/J.Pharmthera.2019.107400 |
0.425 |
|
| 2019 |
Zhong G, Hogarth C, Snyder J, Palau L, Topping T, Huang W, Czuba L, Lafrance J, Ghiaur G, Isoherranen N. The retinoic acid hydroxylase Cyp26a1 has minor effects on postnatal vitamin A homeostasis, but is required for exogenous RA clearance. The Journal of Biological Chemistry. PMID 31167781 DOI: 10.1074/Jbc.Ra119.009023 |
0.359 |
|
| 2019 |
Zhong G, Kirkwood J, Won KJ, Tjota N, Jeong HY, Isoherranen N. Characterization of Vitamin A Metabolome in Human Livers with and without NAFLD. The Journal of Pharmacology and Experimental Therapeutics. PMID 31043436 DOI: 10.1124/Jpet.119.258517 |
0.403 |
|
| 2019 |
Topletz AR, Zhong G, Isoherranen N. Scaling in vitro activity of CYP3A7 suggests human fetal livers do not clear retinoic acid entering from maternal circulation. Scientific Reports. 9: 4620. PMID 30874620 DOI: 10.1038/S41598-019-40995-8 |
0.774 |
|
| 2019 |
Petroff R, Richards T, Crouthamel B, McKain N, Stanley C, Grant KS, Shum S, Jing J, Isoherranen N, Burbacher TM. Chronic, Low-Level Oral Exposure to Marine Toxin, Domoic Acid, Alters Whole Brain Morphometry in Nonhuman Primates. Neurotoxicology. PMID 30826346 DOI: 10.1016/J.Neuro.2019.02.016 |
0.317 |
|
| 2019 |
Ning M, Duarte JD, Stevison F, Isoherranen N, Rubin LH, Jeong H. Determinants of CYP2D6 mRNA levels in healthy human liver tissue. Clinical and Translational Science. PMID 30821899 DOI: 10.1111/Cts.12632 |
0.37 |
|
| 2019 |
Stevison F, Kosaka M, Kenny JR, Wong S, Hogarth C, Amory JK, Isoherranen N. Does in vitro CYP down-regulation translate to in vivo drug-drug interactions? Preclinical and clinical studies with 13-cis-retinoic acid. Clinical and Translational Science. PMID 30681285 DOI: 10.1111/Cts.12616 |
0.413 |
|
| 2019 |
Burbacher TM, Grant KS, Petroff R, Shum S, Crouthamel B, Stanley C, McKain N, Jing J, Isoherranen N. Effects of oral domoic acid exposure on maternal reproduction and infant birth characteristics in a preclinical nonhuman primate model. Neurotoxicology and Teratology. PMID 30615984 DOI: 10.1016/J.Ntt.2019.01.001 |
0.302 |
|
| 2018 |
Grizotte-Lake M, Zhong G, Duncan K, Kirkwood J, Iyer N, Smolenski I, Isoherranen N, Vaishnava S. Commensals Suppress Intestinal Epithelial Cell Retinoic Acid Synthesis to Regulate Interleukin-22 Activity and Prevent Microbial Dysbiosis. Immunity. 49: 1103-1115.e6. PMID 30566883 DOI: 10.1016/J.Immuni.2018.11.018 |
0.329 |
|
| 2018 |
Beedle MT, Stevison F, Zhong G, Topping T, Hogarth C, Isoherranen N, Griswold MD. Sources of All-Trans Retinal Oxidation Independent of the Aldehyde Dehydrogenase 1A Isozymes Exist in the Postnatal Testis. Biology of Reproduction. PMID 30247516 DOI: 10.1093/Biolre/Ioy200 |
0.355 |
|
| 2018 |
Zhong G, Ortiz D, Zelter A, Nath A, Isoherranen N. CYP26C1 is a hydroxylase of multiple active retinoids and interacts with cellular retinoic acid binding proteins. Molecular Pharmacology. PMID 29476041 DOI: 10.1124/Mol.117.111039 |
0.44 |
|
| 2018 |
Zhong G, Ortiz D, Kirkwood J, Zelter A, Nath A, Isoherranen N. Biochemical and kinetic characterization of CYP26C1 in retinoic acid and 4-OXO-all-trans-retinoic acid metabolism Drug Metabolism and Pharmacokinetics. 33: S31. DOI: 10.1016/J.Dmpk.2017.11.117 |
0.332 |
|
| 2018 |
Isoherranen N. Prediction of metabolic drug clearance in humans Drug Metabolism and Pharmacokinetics. 33. DOI: 10.1016/J.Dmpk.2017.11.012 |
0.356 |
|
| 2017 |
Jing J, Petroff R, Shum S, Crouthamel B, Topletz AR, Grant KS, Burbacher TM, Isoherranen N. Toxicokinetics and Physiologically Based Pharmacokinetic Modeling of the Shellfish Toxin Domoic Acid in Nonhuman Primates. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 29150543 DOI: 10.1124/Dmd.117.078485 |
0.735 |
|
| 2017 |
Huang W, Nakano M, Sager JE, Ragueneau-Majlessi I, Isoherranen N. Physiologically Based Pharmacokinetic (Pbpk) Model of the Cyp2d6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 28860113 DOI: 10.1124/Dmd.117.076455 |
0.302 |
|
| 2017 |
Grant KS, Petroff R, Isoherranen N, Stella N, Burbacher TM. Cannabis Use during Pregnancy: Pharmacokinetics and Effects on Child Development. Pharmacology & Therapeutics. PMID 28847562 DOI: 10.1016/J.Pharmthera.2017.08.014 |
0.326 |
|
| 2017 |
Wagner DJ, Sager JE, Duan H, Isoherranen N, Wang J. Interaction and Transport of Methamphetamine and its Primary Metabolites by Organic Cation and Multidrug and Toxin Extrusion Transporters. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 28428365 DOI: 10.1124/Dmd.116.074708 |
0.309 |
|
| 2017 |
Jing J, Nelson C, Paik J, Shirasaka Y, Amory JK, Isoherranen N. Physiologically Based Pharmacokinetic Model of all- trans-Retinoic Acid with Application to Cancer Populations and Drug Interactions. The Journal of Pharmacology and Experimental Therapeutics. PMID 28275201 DOI: 10.1124/Jpet.117.240523 |
0.377 |
|
| 2016 |
Sager JE, Tripathy S, Sl Price L, Nath A, Chang J, Stephenson-Famy A, Isoherranen N. In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Biochemical Pharmacology. PMID 27836670 DOI: 10.1016/J.Bcp.2016.11.007 |
0.394 |
|
| 2016 |
Sager JE, Choiniere JR, Chang J, Stephenson-Famy A, Nelson WL, Isoherranen N. Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans. Acs Medicinal Chemistry Letters. 7: 791-6. PMID 27660681 DOI: 10.1021/Acsmedchemlett.6B00189 |
0.395 |
|
| 2016 |
Sager JE, Price LS, Isoherranen N. Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion and 4'-OH-bupropion in vitro. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 27495292 DOI: 10.1124/Dmd.116.072363 |
0.411 |
|
| 2016 |
Nelson CH, Peng CC, Lutz JD, Yeung CK, Zelter A, Isoherranen N. Direct protein-protein interactions and substrate channelling between cellular retinoic acid binding proteins and CYP26B1. Febs Letters. PMID 27416800 DOI: 10.1002/1873-3468.12303 |
0.309 |
|
| 2016 |
Jing J, Isoherranen N, Robinson-Cohen C, Petrie I, Kestenbaum BR, Yeung CK. Chronic Kidney Disease Alters Vitamin A Homeostasis via Effects on Hepatic RBP4 Protein Expression and Metabolic Enzymes. Clinical and Translational Science. PMID 27277845 DOI: 10.1111/Cts.12402 |
0.345 |
|
| 2016 |
Foti RS, Isoherranen N, Zelter A, Dickmann LJ, Buttrick BR, Diaz P, Douguet D. Identification of Tazarotenic Acid as the First Xenobiotic Substrate of Human Retinoic Acid Hydroxylase CYP26A1 and CYP26B1. The Journal of Pharmacology and Experimental Therapeutics. PMID 26937021 DOI: 10.1124/Jpet.116.232637 |
0.442 |
|
| 2016 |
Tripathy S, Chapman JD, Han CY, Hogarth C, Arnold SL, Onken J, Kent T, Goodlett DR, Isoherranen N. All-trans-retinoic acid Enhances Mitochondrial Function in Models of Human Liver. Molecular Pharmacology. PMID 26921399 DOI: 10.1124/Mol.116.103697 |
0.337 |
|
| 2016 |
Diaz P, Huang W, Keyari CM, Buttrick B, Price L, Guilloteau N, Tripathy S, Sperandio VG, Fronczek FR, Astruc-Diaz F, Isoherranen N. Development and characterization of novel and selective inhibitors of cytochrome P450 CYP26A1, the human liver retinoic acid hydroxylase. Journal of Medicinal Chemistry. PMID 26918322 DOI: 10.1021/Acs.Jmedchem.5B01780 |
0.391 |
|
| 2016 |
Stevison F, Tripathy S, Kent T, Hogarth CA, Griswold MD, Isoherranen N. CYP26 Inhibition Increases Retinoic Acid Concentrations in Target Tissues and Alters Retinoid Signaling The Faseb Journal. 30. DOI: 10.1096/Fasebj.30.1_Supplement.934.3 |
0.338 |
|
| 2015 |
Kent T, Arnold SL, Fasnacht R, Rowsey R, Mitchell D, Hogarth CA, Isoherranen N, Griswold MD. ALDH Enzyme Expression Is Independent of the Spermatogenic Cycle and Their Inhibition Causes Misregulation of Murine Spermatogenic Processes. Biology of Reproduction. PMID 26632609 DOI: 10.1095/Biolreprod.115.131458 |
0.378 |
|
| 2015 |
Shirasaka Y, Chaudhry AS, McDonald M, Prasad B, Wong T, Calamia JC, Fohner A, Thornton TA, Isoherranen N, Unadkat JD, Rettie AE, Schuetz EG, Thummel KE. Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. The Pharmacogenomics Journal. PMID 26323597 DOI: 10.1038/Tpj.2015.58 |
0.364 |
|
| 2015 |
Stevison F, Jing J, Tripathy S, Isoherranen N. Role of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and Cancer. Advances in Pharmacology (San Diego, Calif.). 74: 373-412. PMID 26233912 DOI: 10.1016/Bs.Apha.2015.04.006 |
0.373 |
|
| 2015 |
Arnold SL, Kent T, Hogarth CA, Griswold MD, Amory JK, Isoherranen N. Pharmacological inhibition of ALDH1A in mice decreases all-trans retinoic acid concentrations in a tissue specific manner. Biochemical Pharmacology. 95: 177-92. PMID 25764981 DOI: 10.1016/J.Bcp.2015.03.001 |
0.388 |
|
| 2015 |
Varma MV, Pang KS, Isoherranen N, Zhao P. Dealing with the complex drug-drug interactions: towards mechanistic models. Biopharmaceutics & Drug Disposition. 36: 71-92. PMID 25545151 DOI: 10.1002/Bdd.1934 |
0.338 |
|
| 2015 |
Hogarth CA, Arnold S, Kent T, Mitchell D, Isoherranen N, Griswold MD. Processive pulses of retinoic acid propel asynchronous and continuous murine sperm production. Biology of Reproduction. 92: 37. PMID 25519186 DOI: 10.1095/Biolreprod.114.126326 |
0.307 |
|
| 2015 |
Arnold SL, Kent T, Hogarth CA, Schlatt S, Prasad B, Haenisch M, Walsh T, Muller CH, Griswold MD, Amory JK, Isoherranen N. Importance of ALDH1A enzymes in determining human testicular retinoic acid concentrations. Journal of Lipid Research. 56: 342-57. PMID 25502770 DOI: 10.1194/Jlr.M054718 |
0.346 |
|
| 2015 |
Topletz AR, Tripathy S, Foti RS, Shimshoni JA, Nelson WL, Isoherranen N. Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in the elimination of active retinoids. Molecular Pharmacology. 87: 430-41. PMID 25492813 DOI: 10.1124/Mol.114.096784 |
0.781 |
|
| 2014 |
Tay-Sontheimer J, Shireman LM, Beyer RP, Senn T, Witten D, Pearce RE, Gaedigk A, Gana Fomban CL, Lutz JD, Isoherranen N, Thummel KE, Fiehn O, Leeder JS, Lin YS. Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics. 15: 1947-62. PMID 25521354 DOI: 10.2217/Pgs.14.155 |
0.314 |
|
| 2014 |
Paik J, Haenisch M, Muller CH, Goldstein AS, Arnold S, Isoherranen N, Brabb T, Treuting PM, Amory JK. Inhibition of retinoic acid biosynthesis by the bisdichloroacetyldiamine WIN 18,446 markedly suppresses spermatogenesis and alters retinoid metabolism in mice. The Journal of Biological Chemistry. 289: 15104-17. PMID 24711451 DOI: 10.1074/Jbc.M113.540211 |
0.354 |
|
| 2014 |
Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clinical Pharmacology and Therapeutics. 95: 653-62. PMID 24569517 DOI: 10.1038/Clpt.2014.50 |
0.386 |
|
| 2014 |
Amory JK, Arnold S, Lardone MC, Piottante A, Ebensperger M, Isoherranen N, Muller CH, Walsh T, Castro A. Levels of the retinoic acid synthesizing enzyme aldehyde dehydrogenase-1A2 are lower in testicular tissue from men with infertility. Fertility and Sterility. 101: 960-6. PMID 24524833 DOI: 10.1016/J.Fertnstert.2013.12.053 |
0.324 |
|
| 2014 |
Koh KH, Pan X, Shen HW, Arnold SL, Yu AM, Gonzalez FJ, Isoherranen N, Jeong H. Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice. The Journal of Biological Chemistry. 289: 3105-13. PMID 24318876 DOI: 10.1074/Jbc.M113.526798 |
0.419 |
|
| 2014 |
Lee CM, Lee BS, Arnold SL, Isoherranen N, Morgan ET. Nitric oxide and interleukin-1β stimulate the proteasome-independent degradation of the retinoic acid hydroxylase CYP2C22 in primary rat hepatocytes. The Journal of Pharmacology and Experimental Therapeutics. 348: 141-52. PMID 24144795 DOI: 10.1124/Jpet.113.209841 |
0.371 |
|
| 2014 |
Sager J, Hsu M, Isoherranen N, Wienkers L, Wahlstrom J, Foti R. Application of physiologically-based pharmacokinetic modeling in hepatic impairment populations (1064.9) The Faseb Journal. 28. DOI: 10.1096/Fasebj.28.1_Supplement.1064.9 |
0.306 |
|
| 2013 |
Wen J, Lopes F, Soares G, Farrell SA, Nelson C, Qiao Y, Martell S, Badukke C, Bessa C, Ylstra B, Lewis S, Isoherranen N, Maciel P, Rajcan-Separovic E. Phenotypic and functional consequences of haploinsufficiency of genes from exocyst and retinoic acid pathway due to a recurrent microdeletion of 2p13.2. Orphanet Journal of Rare Diseases. 8: 100. PMID 23837398 DOI: 10.1186/1750-1172-8-100 |
0.308 |
|
| 2013 |
Lutz JD, VandenBrink BM, Babu KN, Nelson WL, Kunze KL, Isoherranen N. Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 2056-65. PMID 23785064 DOI: 10.1124/Dmd.113.052639 |
0.385 |
|
| 2013 |
Shirasaka Y, Chang SY, Grubb MF, Peng CC, Thummel KE, Isoherranen N, Rodrigues AD. Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1566-74. PMID 23723360 DOI: 10.1124/Dmd.112.049940 |
0.38 |
|
| 2013 |
Nelson CH, Buttrick BR, Isoherranen N. Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics. Current Topics in Medicinal Chemistry. 13: 1402-28. PMID 23688132 DOI: 10.2174/1568026611313120004 |
0.385 |
|
| 2013 |
Shirasaka Y, Sager JE, Lutz JD, Davis C, Isoherranen N. Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1414-24. PMID 23620487 DOI: 10.1124/Dmd.113.051722 |
0.393 |
|
| 2013 |
Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Isoherranen N, Unadkat JD. A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 801-13. PMID 23355638 DOI: 10.1124/Dmd.112.050161 |
0.373 |
|
| 2013 |
Isoherranen N, Thummel KE. Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 256-62. PMID 23328895 DOI: 10.1124/Dmd.112.050245 |
0.404 |
|
| 2013 |
Topletz AR, Le HN, Lee N, Chapman JD, Kelly EJ, Wang J, Isoherranen N. Hepatic Cyp2d and Cyp26a1 mRNAs and activities are increased during mouse pregnancy. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 312-9. PMID 23150428 DOI: 10.1124/Dmd.112.049379 |
0.768 |
|
| 2013 |
Dickmann LJ, Isoherranen N. Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 270-4. PMID 22815312 DOI: 10.1124/Dmd.112.047118 |
0.404 |
|
| 2012 |
Shimshoni JA, Roberts AG, Scian M, Topletz AR, Blankert SA, Halpert JR, Nelson WL, Isoherranen N. Stereoselective formation and metabolism of 4-hydroxy-retinoic Acid enantiomers by cytochrome p450 enzymes. The Journal of Biological Chemistry. 287: 42223-32. PMID 23071109 DOI: 10.1074/Jbc.M112.404475 |
0.756 |
|
| 2012 |
Isoherranen N, Lutz JD, Chung SP, Hachad H, Levy RH, Ragueneau-Majlessi I. Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data. Chemical Research in Toxicology. 25: 2285-300. PMID 22823924 DOI: 10.1021/Tx300192G |
0.35 |
|
| 2012 |
Fujioka Y, Kunze KL, Isoherranen N. Risk assessment of mechanism-based inactivation in drug-drug interactions. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1653-7. PMID 22685217 DOI: 10.1124/Dmd.112.046649 |
0.31 |
|
| 2012 |
Lutz JD, Isoherranen N. In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors. Expert Opinion On Drug Metabolism & Toxicology. 8: 449-66. PMID 22384784 DOI: 10.1517/17425255.2012.667801 |
0.31 |
|
| 2012 |
Peng CC, Shi W, Lutz JD, Kunze KL, Liu JO, Nelson WL, Isoherranen N. Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 426-35. PMID 22106171 DOI: 10.1124/Dmd.111.042739 |
0.372 |
|
| 2012 |
Topletz AR, Thatcher JE, Zelter A, Lutz JD, Tay S, Nelson WL, Isoherranen N. Comparison of the function and expression of CYP26A1 and CYP26B1, the two retinoic acid hydroxylases. Biochemical Pharmacology. 83: 149-63. PMID 22020119 DOI: 10.1016/J.Bcp.2011.10.007 |
0.786 |
|
| 2012 |
Lutz JD, Isoherranen N. Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 159-68. PMID 22010218 DOI: 10.1124/Dmd.111.042200 |
0.42 |
|
| 2011 |
Yang J, Atkins WM, Isoherranen N, Paine MF, Thummel KE. Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam. Clinical Pharmacology and Therapeutics. 91: 442-9. PMID 22048224 DOI: 10.1038/Clpt.2011.178 |
0.384 |
|
| 2011 |
Thatcher JE, Buttrick B, Shaffer SA, Shimshoni JA, Goodlett DR, Nelson WL, Isoherranen N. Substrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase. Molecular Pharmacology. 80: 228-39. PMID 21521770 DOI: 10.1124/Mol.111.072413 |
0.402 |
|
| 2011 |
Foti RS, Honaker M, Nath A, Pearson JT, Buttrick B, Isoherranen N, Atkins WM. Catalytic versus inhibitory promiscuity in cytochrome P450s: implications for evolution of new function. Biochemistry. 50: 2387-93. PMID 21370922 DOI: 10.1021/Bi1020716 |
0.311 |
|
| 2011 |
Yeung CK, Fujioka Y, Hachad H, Levy RH, Isoherranen N. Are circulating metabolites important in drug-drug interactions: Quantitative analysis of risk prediction and inhibitory potency Clinical Pharmacology and Therapeutics. 89: 105-113. PMID 21124313 DOI: 10.1038/Clpt.2010.252 |
0.364 |
|
| 2011 |
Walker AA, Leslie D, Isoherranen N. Pregnancy decreases rat CYP1A2 activity and expression Drug Metabolism and Disposition. 39: 4-7. PMID 20921303 DOI: 10.1124/Dmd.110.035766 |
0.767 |
|
| 2011 |
Amory JK, Muller CH, Shimshoni JA, Isoherranen N, Paik J, Moreb JS, Amory DW, Evanoff R, Goldstein AS, Griswold MD. Suppression of spermatogenesis by bisdichloroacetyldiamines is mediated by inhibition of testicular retinoic acid biosynthesis. Journal of Andrology. 32: 111-9. PMID 20705791 DOI: 10.2164/Jandrol.110.010751 |
0.365 |
|
| 2011 |
Yeung CK, Fujioka Y, Hachad H, Levy RH, Isoherranen N. Are circulating metabolites important in drug-drug interactions? Quantitative analysis of risk prediction and inhibitory potency (Clinical Pharmacology and Therapeutics (2011) 89, (105-113) DOI: 10.1038/clpt.2010.252) Clinical Pharmacology and Therapeutics. 89: 468. DOI: 10.1038/Clpt.2010.349 |
0.303 |
|
| 2010 |
Templeton I, Peng CC, Thummel KE, Davis C, Kunze KL, Isoherranen N. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clinical Pharmacology and Therapeutics. 88: 499-505. PMID 20739919 DOI: 10.1038/Clpt.2010.119 |
0.393 |
|
| 2010 |
Lutz JD, Fujioka Y, Isoherranen N. Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters. Expert Opinion On Drug Metabolism & Toxicology. 6: 1095-109. PMID 20557268 DOI: 10.1517/17425255.2010.497487 |
0.336 |
|
| 2010 |
Thatcher JE, Zelter A, Isoherranen N. The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid. Biochemical Pharmacology. 80: 903-12. PMID 20513361 DOI: 10.1016/J.Bcp.2010.05.023 |
0.425 |
|
| 2010 |
Zhou L, Naraharisetti SB, Liu L, Wang H, Lin YS, Isoherranen N, Unadkat JD, Hebert MF, Mao Q. Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharmaceutics & Drug Disposition. 31: 228-42. PMID 20437462 DOI: 10.1002/Bdd.706 |
0.456 |
|
| 2010 |
VandenBrink BM, Isoherranen N. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition. Current Opinion in Drug Discovery & Development. 13: 66-77. PMID 20047147 |
0.302 |
|
| 2010 |
Tay S, Dickmann L, Dixit V, Isoherranen N. A comparison of the roles of peroxisome proliferator-activated receptor and retinoic acid receptor on CYP26 regulation. Molecular Pharmacology. 77: 218-27. PMID 19884280 DOI: 10.1124/Mol.109.059071 |
0.415 |
|
| 2009 |
Thatcher JE, Isoherranen N. The role of CYP26 enzymes in retinoic acid clearance. Expert Opinion On Drug Metabolism & Toxicology. 5: 875-86. PMID 19519282 DOI: 10.1517/17425250903032681 |
0.374 |
|
| 2009 |
Isoherranen N, Hachad H, Yeung CK, Levy RH. Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database. Chemical Research in Toxicology. 22: 294-8. PMID 19216580 DOI: 10.1021/Tx800491E |
0.398 |
|
| 2009 |
Lutz JD, Dixit V, Yeung CK, Dickmann LJ, Zelter A, Thatcher JE, Nelson WL, Isoherranen N. Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase. Biochemical Pharmacology. 77: 258-68. PMID 18992717 DOI: 10.1016/J.Bcp.2008.10.012 |
0.398 |
|
| 2008 |
Dickmann LJ, Tay S, Senn TD, Zhang H, Visone A, Unadkat JD, Hebert MF, Isoherranen N. Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy. Biochemical Pharmacology. 75: 1677-87. PMID 18342837 DOI: 10.1016/J.Bcp.2008.01.012 |
0.413 |
|
| 2008 |
Hashizume T, Xu Y, Mohutsky MA, Alberts J, Hadden C, Kalhorn TF, Isoherranen N, Shuhart MC, Thummel KE. Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation. Biochemical Pharmacology. 75: 1240-50. PMID 18177842 DOI: 10.1016/J.Bcp.2007.11.008 |
0.353 |
|
| 2008 |
Isoherranen N, Ludington SR, Givens RC, Lamba JK, Pusek SN, Dees EC, Blough DK, Iwanaga K, Hawke RL, Schuetz EG, Watkins PB, Thummel KE, Paine MF. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 146-54. PMID 17954524 DOI: 10.1124/Dmd.107.018382 |
0.401 |
|
| 2008 |
Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL, Isoherranen N. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clinical Pharmacology and Therapeutics. 83: 77-85. PMID 17495874 DOI: 10.1038/Sj.Clpt.6100230 |
0.439 |
|
| 2007 |
Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, Whittington D, Ensign D. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clinical Pharmacology and Therapeutics. 82: 410-26. PMID 17554244 DOI: 10.1038/Sj.Clpt.6100237 |
0.759 |
|
| 2006 |
Pearson JT, Hill JJ, Swank J, Isoherranen N, Kunze KL, Atkins WM. Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations. Biochemistry. 45: 6341-53. PMID 16700545 DOI: 10.1021/Bi0600042 |
0.302 |
|
| 2006 |
Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, Thummel KE. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 836-47. PMID 16501005 DOI: 10.1124/Dmd.105.008680 |
0.425 |
|
| 2006 |
Kunze KL, Nelson WL, Kharasch ED, Thummel KE, Isoherranen N. Stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 583-90. PMID 16415110 DOI: 10.1124/Dmd.105.008508 |
0.356 |
|
| 2004 |
Huang W, Lin YS, McConn DJ, Calamia JC, Totah RA, Isoherranen N, Glodowski M, Thummel KE. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 32: 1434-45. PMID 15383492 DOI: 10.1124/Dmd.104.001313 |
0.426 |
|
| 2004 |
Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 32: 1121-31. PMID 15242978 DOI: 10.1124/Dmd.104.000315 |
0.397 |
|
| 2004 |
Isoherranen N, Levy RH, Yagen B, Woodhead JH, White HS, Bialer M. Metabolism of a new antiepileptic drug, N-methyl-tetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites. Epilepsy Research. 58: 1-12. PMID 15066669 DOI: 10.1016/J.Eplepsyres.2003.12.001 |
0.41 |
|
| 2003 |
Isoherranen N, Spiegelstein O, Bialer M, Zhang J, Merriweather M, Yagen B, Roeder M, Triplett AA, Schurig V, Finnell RH. Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity. Epilepsia. 44: 1280-8. PMID 14510821 DOI: 10.1046/J.1528-1157.2003.21503.X |
0.323 |
|
| 2003 |
Isoherranen N, White HS, Klein BD, Roeder M, Woodhead JH, Schurig V, Yagen B, Bialer M. Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy. Pharmaceutical Research. 20: 1293-301. PMID 12948028 DOI: 10.1023/A:1025069519218 |
0.315 |
|
| 2003 |
Isoherranen N, Yagen B, Spiegelstein O, Finnell RH, Merriweather M, Woodhead JH, Wlodarczyk B, White HS, Bialer M. Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice. British Journal of Pharmacology. 139: 755-64. PMID 12812999 DOI: 10.1038/Sj.Bjp.0705301 |
0.353 |
|
| 2003 |
Britzi M, Soback S, Isoherranen N, Levy RH, Perucca E, Doose DR, Maryanoff BE, Bialer M. Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay Therapeutic Drug Monitoring. 25: 314-322. PMID 12766560 DOI: 10.1097/00007691-200306000-00012 |
0.303 |
|
| 2003 |
Isoherranen N, Yagen B, Bialer M. New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? Current Opinion in Neurology. 16: 203-11. PMID 12644750 DOI: 10.1097/01.Wco.0000063774.81810.30 |
0.308 |
|
| 2003 |
Isoherranen N, Yagen B, Bialer M. New CNS-active drugs which are second-generation valproic acid Current Opinion in Neurology. 16: 203-211. DOI: 10.1097/00019052-200304000-00014 |
0.307 |
|
| 2001 |
Isoherranen N, Woodhead JH, White HS, Bialer M. Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia. 42: 831-6. PMID 11488880 DOI: 10.1046/J.1528-1157.2001.042007831.X |
0.305 |
|
| Show low-probability matches. |